Lilly (Eli)
Eli Lilly and Company (NYSE: LLY) discovers, develops, manufactures, and markets human pharmaceutical products. Its medicines address cardiometabolic health, oncology, immunology, and neuroscience, with products including Mounjaro, Zepbound, Jardiance, Verzenio, Taltz, and Kisunla. The company operates as a single… From the company’s description.
In fiscal 2025, Lilly (Eli) reported revenue of $65.18B, up 44.7% from fiscal 2024, and net income of $20.64B. Its operating margin was 40.4%, and operations generated $16.81B in cash. Over the twelve months to Jun 30, 2026, revenue was $79.67B.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Lilly (Eli) does
In the company’s own words
Eli Lilly and Company (NYSE: LLY) discovers, develops, manufactures, and markets human pharmaceutical products. Its medicines address cardiometabolic health, oncology, immunology, and neuroscience, with products including Mounjaro, Zepbound, Jardiance, Verzenio, Taltz, and Kisunla. The company operates as a single reportable business segment focused on human pharmaceuticals. Its customers and distribution channels include wholesalers, pharmacies, physicians, hospitals, healthcare professionals, insurers, pharmacy benefit managers, employers, government and long-term care institutions, and patients. In the United States, it also provides delivery of select medicines through LillyDirect, a digital health care platform using third-party pharmacies. Lilly manufactures and distributes products through facilities in the United States, including Puerto Rico, Europe, and Asia, and sells products in approximately 90 countries. Founded in 1876 as a drug manufacturing business, the company was incorporated in Indiana in 1901 to succeed that business.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- INDIANAPOLIS, IN
- Fiscal year end
- December
- CIK
- 59478
- SIC
- 2834
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Lilly (Eli) — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in Lilly (Eli) · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · Lilly (Eli)’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Lilly (Eli)’s bonds, as funds hold them
Funds report holding 54 issues of Lilly (Eli)’s debt, $5.20B at market value — what funds hold, not the company’s total debt. Weighted-average coupon 4.67%, maturing 2026 to 2066.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Lilly (Eli) and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Lilly (Eli)'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Lilly (Eli)'s last four quarterly filings that the numbers alone won't show?”